With the new direction in research and clinical trials, treating patients who most benefit from treatment with minimal toxicity will continue to be the mainstay of personalized cancer therapy.
Jörg J. Jacoby, PhD
Advertisement
Articles by Jörg J. Jacoby, PhD
Advertisement
Latest Updated Articles
- Future Directions of Monoclonal Antibody Use in Personalized Lung Cancer Therapy
Published: November 30th 2010 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
FDA Approves Revumenib in R/R NPM1-Mutant AML
3
Convergent and Divergent Signaling Pathways in Cancer: A Dual-Axis Model for Adaptive Precision Oncology
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
